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Background: The neuronal cytoplasmic localization of SET, an inhibitor of the phosphatase 2A (PP2A), results in tau
hyperphosphorylation in the brains of Alzheimer patients through mechanisms that are still not well defined.
Results: We used primary neurons and mouse brain slices to show that SET is translocated to the cytoplasm in a
manner independent of both its cleavage and over-expression. The localization of SET in the cytoplasm, either by
the translocation of endogenous SET or by internalization of the recombinant full-length SET protein, induced tau
hyperphosphorylation. Cytoplasmic recombinant full-length SET in mouse brain slices induced a decrease of PP2A
activity through a decrease of methylated PP2A levels. The levels of methylated PP2A were negatively correlated
with tau hyperphosphorylation at Ser-202 but not with the abnormal phosphorylation of tau at Ser-422.
Conclusions: The presence of full-length SET in the neuronal cytoplasm is sufficient to impair PP2A methylation
and activity, leading to tau hyperphosphorylation. In addition, our data suggest that tau hyperphosphorylation is
regulated by different mechanisms at distinct sites. The translocation of SET to the neuronal cytoplasm, the low
activity of PP2A, and tau hyperphosphorylation are associated in the brains of Alzheimer patients. Our data show a
link between the translocation of SET in the cytoplasm and the decrease of methylated PP2A levels leading to a
decrease of PP2A activity and tau hyperphosphorylation. This chain of events may contribute to the pathogenesis
of Alzheimer disease.
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Hyperphosphorylation of tau, which leads to the forma-
tion of neurofibrillary tangles, is one of the two hallmarks
of Alzheimer disease (AD) [1-3]. Tau phosphorylation is
mainly regulated by the balance of kinases/phosphatases.
Several kinases are involved in tau phosphorylation in-
cluding the glycogen synthase kinase 3β (GSK-3β),
MAP kinase (MEK1/2), neuronal cdc2-like kinase (NCLK)
and cyclin dependent kinase 5 (cdk5) [1-3]. In contrast,
few phosphatases dephosphorylate tau. Phosphatase 2A
(PP2A), a serine/threonine phosphatase, is the most
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article, unless otherwise stated.PP2A is a trimeric protein with a heterodimeric core
enzyme consisting of a catalytic C subunit (PP2Ac), and a
scaffolding A subunit. This core enzyme associates with a
variable regulatory subunit to form a heterotrimeric holo-
enzyme [4-6]. PP2A shows efficient enzymatic activity
when it is methylated at Leu-309 [7-10] and unphosphory-
lated at Tyr-307 [11]. In the brain of AD patients, the ac-
tivity of PP2A is compromised [12-14]. The decrease of
PP2A methylation observed in brains of AD patients [15]
may explain the decrease of PP2A activity and contribute
to tau hyperphosphorylation [16,17].
The activity of PP2A can be inhibited by two proteins:
I1PP2A and I2PP2A, which is also called SET, TAF1β, or
PHAPII [18]. SET is a multifunctional protein: it inhibits
the acetylation of histones [19], blocks DNase activity
[20], acts as a transcription factor [21], and promotes tau
phosphorylation by activating cdk5 [22], and inhibiting
PP2A [23].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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expression [24,25]. Interestingly, SET is also translocated
from the nucleus to the cytoplasm in the hippocampus
and the temporal cortex of AD patients [25,26]. We ob-
served that in the CA1 of AD patients, the translocation
of SET to the cytoplasm was associated with an increase
of Amyloid Precursor Protein (APP) cleaved in its cyto-
plasmic domain by a caspase (APPcc) [26]. In in vitro
models, cytoplasmic SET is associated with neuronal
death [27-29] and with tau hyperphosphorylation [30,31].
The 39 kDa full-length SET can be selectively cleaved
resulting in a ~ 20 kDa fragment in the cytosol of neurons
in the brain [25]. The cleavage of SET protein has also
been observed in primary neurons treated with kainate
and in a mouse model of stroke [32]. This cleavage results
from the activation of an asparaginyl endopeptidase (AEP)
which cuts SET at asparagine Asn-175, generating NTF
and CTF fragments and triggering DNA nicking and cell
death [33]. Both NTF and CTF are able to bind to the
catalytic subunit of PP2A (PP2Ac) inhibiting its activity
and leading to tau hyperphosphorylation [34-36]. How-
ever, it is not clear whether the cytoplasmic localization
of SET is always associated with its cleavage, with its
over-expression, and with tau hyperphosphorylation.
It is still not clear how cytoplasmic SET contributes to
PP2A loss of function leading to tau hyperphosphoryla-
tion, and whether the presence of SET in the cytoplasm
induces low levels of methylated PP2A. We used two
models to clarify the relationship between cytoplasmic
SET, methylated PP2A, PP2A activity and tau hyperphos-
phorylation. The first model involved the translocation of
endogenous SET from the nucleus to the cytoplasm in pri-
mary neurons or brain slices from wild type mice (WT).
This translocation was induced in this model by the in-
ternalization of the Jcasp peptide. Indeed, this peptide
mimics the unmasked juxtamembrane cytoplasmic do-
main arising from the cleavage of APP by caspases, which
is increased in the brains of AD patients [37-39,26].
Moreover, this peptide is sufficient to induce in vivo
both translocation of endogenous SET, as occurs in the
CA1 of WT mice following APPcc overexpression, and
neurodegeneration [26,27,40]. The second model in-
volved the over-expression of SET by the internalization
of exogenous recombinant full-length protein in brain
slices from WT mice [27]. In these two models, we report
that cytoplasmic SET induces the hyperphosphorylation of
tau in the absence of detectable cleaved forms of SET. We
also show that the interaction of SET with PP2A impairs
the methylation of PP2A and that the level of methylated
PP2A that is associated with the translocation of SET is
also negatively correlated with the hyperphosphorylation
of tau at Ser-202, but not at Ser-422, suggesting that the
hyperphosphorylation of tau is regulated by different
mechanisms at distinct residues.Results
Internalization of Jcasp peptide induces the translocation
of endogenous nuclear SET to the cytoplasm without
cleavage or upregulation of its expression
We previously reported that the cytoplasmic internaliza-
tion of the Jcasp peptide by primary neurons resulted in
the translocation of endogenous SET to the cytoplasm
and triggered pro-apoptotic signals at the cell membrane
[27,28]. Thus, in this model, SET promotes apoptosis, and
its translocation to the cytoplasm appears to participate in
the active neurodegenerative process [27,28].
In this model, we also previously showed that the
Jcasp peptide fused to the Penetratin vector is quickly
internalized, and that endogenous SET starts to move
from the nucleus to the cytoplasm after 3 h, while apop-
tosis was observed 24 h later [27]. Here, we show that
translocated SET is still present in the cytoplasm of the
cellular body and in neurites 5 h 30 min after Jcasp pep-
tide internalization (Figure 1A). Sub-cellular fraction-
ation and western blotting revealed the presence of a
39 kDa band corresponding to endogenous SET in the
cytoplasm fraction of cells treated with Jcasp peptide
(Figure 1B). The proportion of translocated SET was
39% of total endogenous SET (Figure 1B), which was in
accordance with observations made by epifluorescence
microscopy (Figure 1A). Cleavage products of SET in
the nucleus and in the cytoplasm were not detected
(Figure 1B). Real-time PCR showed that the level of
SET transcripts was unchanged during the 5 h 30 min
of Jcasp peptide internalization (Figure 1C).
Hence, in this model, the translocation of SET from
the nucleus to the cytoplasm does not require its over-
expression and/or its cleavage.
Over-expression of recombinant cytoplasmic SET in
primary mouse neurons and mouse brain slices does not
induce its cleavage
We introduced a recombinant HA-tagged SET protein
fused to the Penetratin vector into the cytoplasm of pri-
mary neurons by direct internalization as previously de-
scribed [27]. We detected the 49 kDa recombinant SET
protein by immunocytochemistry with an anti-HA anti-
body and analyzed its distribution by confocal micros-
copy. After 3 h of internalization, the recombinant SET
protein, which possesses a nuclear targeting sequence,
was mostly concentrated in the cell body around the
nucleus and had started to move inside the nucleus
(Figure 2A). After 5 h 30 min of internalization, the nu-
cleus was enriched with the recombinant SET protein,
although recombinant SET was still abundantly present
in the cytoplasm (Figure 2B). We confirmed these ob-
servations with mouse brain slices that were treated
with the recombinant SET protein. Sub-cellular frac-
tionation followed by western blotting with an anti-HA
Figure 1 Endogenous SET translocation after 5 h 30 min of Jcasp peptide internalization in mouse primary neurons. A)
Immunocytochemical staining (epifluorescence) of endogenous SET (Cy3) in primary neurons treated with the Jcasp peptide (2 μM) for 5 h
30 min, and control neurons in the absence of any peptide. Nuclei were labeled with DAPI. SET is mostly present in the nucleus of control
neurons in the absence of any peptide as indicated in combined images (Merge), whereas SET translocation to the cytoplasm occurs after the
internalization of Jcasp peptide (see arrowheads). One representative immunocytochemical staining out of five independent experiments is
presented. Scale bar, 10 μm. B) Representative western blot of cytoplasmic (Cyt) and nuclear (N) neuronal extracts obtained by sub-cellular
fractionation (n = 3 independent experiments). Endogenous SET was detected with a SET antibody. Dab1 was used as a cytoplasmic control and
histone was used as a nuclear control. A total of 10 μg of protein was loaded in each lane. Endogenous SET at 39 kDa is partially localized in the
cytoplasm in cells containing Jcasp peptide. Cleaved SET fragments cannot be detected. C) Relative expression of SET mRNA assessed by
quantitative real-time PCR in cells treated with Jcasp peptide for 1 h 30 min, 2 h 30 min, 3 h 30 min and 5 h 30 min and with the Penetratin
(Pen) peptide only at the same time points. Results are expressed as the ratio of SET mRNA in Jcasp peptide internalization versus Penetratin only
assays at the different time points. Data presented are the mean ± SEM of three independent experiments. Jcasp peptide does not affect the level
of SET mRNA.
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the cytoplasm (Figure 2C-F). The detected bands of low
molecular weight and low intensity were unspecific
bands resulting from the anti-rabbit secondary antibody
(Figure 2F). We did not observe cleaved recombinant
SET protein in either sub-cellular compartment studied
(Figure 2E).Interaction between uncleaved cytoplasmic recombinant
SET protein and PP2A inhibits the activity of PP2A and
impairs its methylation in the brain slices of adult mice
Following its translocation to the cytoplasm, endogenous
SET interacts with the catalytic subunit of PP2A inducing
its inhibition [23,34]. We used direct internalization for
5 h 30 min to overexpress recombinant SET protein
Figure 2 (See legend on next page.)
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Figure 2 Localization of the recombinant SET protein after its internalization. Recombinant SET protein (4 μM) was internalized for 3 h and
5 h 30 min in mouse primary neurons (A, B) and for 5 h 30 min in mouse brain slices (E, F). Confocal microscopy shows immunocytochemical
staining of recombinant SET carried-out with an anti-tag HA antibody. Nuclei were labeled with TO-PRO-3. Four examples at 3 h (A) and at 5 h
30 min (B) are shown. At 3 h, recombinant SET protein is mostly located in the cytoplasm around the nucleus, whereas at 5 h 30 min SET is
distributed in both the cytoplasm and nucleus. One representative immunocytochemical staining out of three independent experiments is
presented. Scale bar, 10 μm. (C) Electrophoresis of tag-HA recombinant SET protein (10 μg of protein was loaded). Coomassie blue shows a major
band at 49 kDa, as expected. D-F) Tag-HA recombinant SET protein (0.4 μg) was detected by western blotting with a tag-HA antibody (D).
Sub-cellular fractions were prepared from brain slices treated for 5 h 30 min with recombinant SET protein and 10 μg of proteins were loaded in
each lane. Recombinant SET was detected with a tag-HA antibody (E). APP was used as a cytoplasmic (Cyt) control and histone was used as a
nuclear (N) control. Recombinant full-length SET protein is observed at 49 kDa in nuclear and cytoplasmic fractions as in (B). Unspecific bands
recognized by the secondary antibody are shown in (F). For (D-F), one representative immunoblot out of five independent experiments is shown
and for (C), one protein staining of recombinant SET out of three independent experiments is presented (C).
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oxygenation conditions, as described in Methods. We first
analyzed total phosphatase activity (Figure 3A). We used
okadaic acid (OA), a marine sponge toxin which is an
inhibitor of PP2A, as a positive control (1 μM for 2 h)
[41]. OA inhibited total phosphatase activity by 33.6% ±
3.7% (n = 11) and recombinant SET inhibited total
phosphatase activity by 13.1% ± 3.3% (n = 11). Hence,
phosphatase activity was significantly impaired in both
cases and was 68.4% ± 3.7% of the baseline value (standard-
ized to 100%) for OA (n = 11, p < 0.0001), and was 86.9% ±
3.3% for recombinant SET (n = 11, p = 0.0008) (Figure 3A).
We then evaluated PP2A activity (which represents 70%
of total phosphatase activity [42]) after PP2A immuno-
precipitation in brain slices treated with OA and in
those containing internalized recombinant SET protein.
The remaining PP2A activity was 33.8% ± 9.8% (n = 3,
p = 0.0025) in brain slices treated with OA and 84% ±
3.8% in brain slices containing recombinant SET (n = 3,
p = 0.0124) (Figure 3B). These values fit with what we
observed for total phosphatase activity. Thus, these data
suggest that when SET is in the cytoplasm, it specifically
impairs PP2A activity in a manner that does not depend
on its cleavage (Figure 2E).
The activity of PP2A depends on its methylation
[7-10]. Therefore, we assessed whether the interaction
between cytoplasmic recombinant SET protein and
endogenous PP2A impaired the methylation of PP2A,
resulting in a decrease in its activity. We used an
antibody directed against total PP2A (methylated
and not methylated) and an antibody specifically
directed against methyl-PP2A, and evaluated the ratio
of methyl-PP2A to total PP2A by western blotting
(Figure 3C, D). After 5 h 30 min of recombinant SET
protein internalization, the ratio of methyl-PP2A to
total PP2A was 83.6% ± 5.2% (n = 9) of the control ra-
tio (standardized to 100%) in the absence of recom-
binant SET (Figure 3D). The mean decrease of this
ratio (16.4%) was significant (p = 0.0057) suggesting
that the presence of SET in the cytoplasm in theabsence of detectable SET cleavage impairs the methy-
lation of PP2A.
Finally, we performed co-immunoprecipitation expe-
riments to check that the internalized recombinant SET
protein interacted with PP2A and impaired the methyla-
tion of PP2A. To this end, we internalized the recom-
binant SET protein in brain slices for 5 h 30 min, and
we extracted proteins from these slices and from con-
trol slices not internalized with recombinant SET. After
lysis, we checked first the total level of PP2A (Figure 3E,
lanes 1, 2) and methyl-PP2A (Figure 3E, lanes 7, 8) in
brain slices by western blotting. We subsequently im-
munoprecipitated SET from slice extracts with an anti-
body that recognizes both endogenous and recombinant
SET. We then analyzed the immunoprecipitates by
western blotting with an antibody that recognizes total
PP2A (Figure 3E, lanes 3–6) and after membrane strip-
ping, with an antibody that specifically recognizes
methyl-PP2A (Figure 3E, lanes 9–12). Only a small
amount of PP2A co-immunoprecipitated with the SET
antibody (Figure 3E, lane 4) in extracts from brain slices
lacking recombinant SET, because only a small pro-
portion of endogenous SET is cytoplasmic. More PP2A
co-immunoprecipitated with SET in cells containing re-
combinant SET protein than in cells lacking the recom-
binant protein (Figure 3E, lane 6), showing that PP2A can
bind to both recombinant and endogenous SET protein.
In contrast, more methyl-PP2A co-immunoprecipitated
with SET in the control (Figure 3E, lane 10) than in cells
containing recombinant SET protein (Figure 3E, lane 12).
The mean ratio of methyl-PP2A to total PP2A was 2.18 ±
0.22 (n = 3) for the control (Figure 3E, lane 10 to lane 4)
and 0.59 ± 0.10 for brain slices treated for 5 h 30 min with
recombinant SET protein (Figure 3E, lane 12 to lane 6).
Thus, the level of co-immunoprecipitated methylated
PP2A was significantly lower in slices internalized with
SET protein than in the control (p = 0.0027) (Figure 3F).
These data confirm that cytoplasmic, uncleaved, recom-
binant SET protein interacts with PP2A and impairs its
methylation.
Figure 3 Phosphatase activities and PP2A methylation in adult mouse brain slices treated with recombinant SET protein for 5 h 30
min. A) The release of p-nitrophenol (nmoles of p-nitrophenol/mg of protein) was assessed. Results are expressed as a percentage of control (Ctrl)
activity that was set to 100%. Mean ± SEM of 11 independent experiments; okadaic acid (OA); OA versus Ctrl: p < 0.0001; SET versus Ctrl:
p = 0.0008. B) Release of p-nitrophenol measured on immunoprecipitated PP2A. Mean ± SEM of three independent experiments; OA versus Ctrl:
p = 0.0025; SET versus Ctrl: p = 0.0124. C) Representative western blot (40 μg of protein loaded) of total and methylated PP2A (methyl-PP2A) and
quantification of the ratio of methylated PP2A to total PP2A D). Mean ± SEM of nine independent experiments. SET versus Ctrl: p = 0.0057.
E) Representative western blot of total PP2A and methyl-PP2A co-immunoprecipitated with a SET primary antibody (out of three independent
experiments). Mouse brain slices in the absence (−) or the presence of recombinant SET protein (+) were immunoprecipitated with a SET
antibody. Co-immunoprecipitated proteins were analyzed by western blotting, with a total PP2A antibody (lanes 3–6) and with a methylated
PP2A (methyl-PP2A) antibody after membrane stripping (lanes 9–12). PP2A (lanes 3 and 5) and methyl-PP2A (lanes 9 and 11) are not detectable
in absence of primary SET antibody (IP Ctrl). Similar levels of total PP2A (lanes 1 and 2) and methyl-PP2A (lanes 7 and 8) in total extracts before
SET immunoprecipitation. F) Quantification of the ratio of methyl-PP2A to total PP2A co-immunoprecipitated with SET primary antibody in mouse
brain slices treated with recombinant SET protein for 5 h 30 min and control (Ctrl) brain slices (no internalization). Meam ± SEM of three
independent experiments; SET versus Ctrl: p = 0.0027.
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abnormal phosphorylation of tau protein. Correlation
with decreased methyl-PP2A levels
Many phosphorylation sites of tau in paired helical fila-
ments (PHF) have been identified in the brains of AD
patients [1-3]. Inhibition of PP2A leads to the preferen-
tial hyper-phosphorylation of tau at various epitopes.
Phosphorylation at Ser-202 and Ser-404 is more preva-
lent in PHF-tau and fetal tau than in normal adult tau
[43,44]; therefore, we analyzed hyper-phosphorylation
of tau at both these sites. We then focused on Ser-202
because PP2A alone regulates dephosphorylation at this
site [44]. We used the AT8 antibody, which is com-
monly used for the immunohistological analysis of AD
patient brains. This antibody can recognize monophos-
phorylated tau at Ser-202 [45]. We also focused our
analysis on the abnormal phosphorylation at Ser-422,
because the phosphorylation of this site is observed only
in PHF-tau and is almost undetectable in biopsy-derived
adult human tau [46].
We prepared lysates from brain slices internalized with
Jcasp peptide or recombinant SET protein for 5 h
30 min and analyzed tau phosphorylation by western
blotting with various antibodies (see Methods) directed
against the epitopes mentioned above. We used OA,
which increases tau phosphorylation at several physio-
logical sites and induces phosphorylation at abnormal
sites, as a positive control. We used the JA peptide as a
negative control; this peptide is a mutated form of the
Jcasp peptide in which a tyrosine is replaced with an ala-
nine resulting in a peptide that induces neither the dele-
terious effect of the Jcasp peptide nor SET translocation
[40,27]. We observed an increase of phosphorylated tau
in cells containing the Jcasp peptide or recombinant
SET protein (Figure 4A) whereas tau phosphorylation in
cells containing the JA peptide was similar to that of the
control. We defined tau phosphorylation of the control
as 100%. Hyper-phosphorylation at Ser-202 that was in-
duced by the recombinant SET protein was 177.6 ± 27.1%
(n = 8; p = 0.02), and that induced by recombinant SET at
Ser-422 was 148.3 ± 27.3% (n = 7) (Figure 4B). However
the hyperphosphorylation at Ser-422 was lower than that
at Ser-202, except for one animal out of the seven studied.
The hyper- and/or abnormal phosphorylation of tau pro-
tein induced by recombinant SET protein or Jcasp peptide
usually involve the same tau protein isoforms as those
affected by OA. However, in some experiments, the
isoforms affected by OA differed from those affected
by recombinant SET protein or the Jcasp peptide, as ob-
served for the 50 kDa tau isoform at Ser-404 (Additional
file 1: Figure S1A), Ser-356, and Ser-235 (Additional
file 1: Figure S1A) and the 70 kDa tau isoform at Ser-202
(Additional file 1: Figure S1B). The level of PP2A was
similar in all conditions (Figure 4A). Interestingly, wefound a significant negative correlation between the per-
centage of methylated PP2A and the percentage of tau
protein hyper-phosphorylated at Ser-202 that was detected
with the AT8 antibody (R2 = 0.89, n = 7) (Figure 4C). How-
ever, there was no correlation with the percentage of tau
protein abnormally phosphorylated at Ser-422 (R2 = −0.06,
n = 7) (Figure 4D), confirming that PP2A preferentially
acts on the phosphorylation of tau at Ser-202.
Discussion
We report here that the presence of SET in the cytoplasm,
in absence of its over-expression or cleavage, decreases
the activity of PP2A and thus stimulates tau hyperphos-
phorylation. Cytoplasmic SET impairs the methylation
of PP2A, and the level of methylated PP2A is negatively
correlated with tau hyperphosphorylation at Ser-202 but
not at Ser-422.
An increase of SET expression leading to an increase
of SET protein has been described in the brains of AD
patients, and is associated with the cytoplasmic transloca-
tion of SET [25]. More recently, we also observed an in-
crease of SET associated with its cytoplasmic translocation
in the hippocampus of Down syndrome patients and in
the CA1 of AD patients [26]. However, we cannot exclude
that particular stress signals trigger the delocalization of
SET in the absence of its over-expression in some subre-
gions of the brains of AD patients [26]. The translocation
of endogenous SET was induced by a cell death signal in
the Jcasp model [28] in absence of SET over-expression.
Similarly, we reported that the over-expression of APPcc
with a lentiviral construct in the CA1 of mice resulted
in the translocation of endogenous SET in the absence
of SET increase [26]. Phosphorylation of SET at Ser-9
by casein kinase II causes the cytoplasmic retention of
SET in the neuronal cytoplasm of the brains of AD pa-
tients [47]. We did not investigate the phosphorylation of
SET at Ser-9 following the translocation of SET from the
nucleus to the cytoplasm, or after its uptake by neurons.
The role of SET cleavage is not clear. Full-length SET
and its cleaved forms can bind to PP2A, inhibiting its
activity and thus increasing tau phosphorylation [34]. It
is not clear whether this cleavage occurs in the nucleus
or in the cytoplasm and whether both fragments remain
in the same subcellular compartment. However, trans-
fection experiments show that full-length SET is found
within the nucleus as expected, whereas the NTF is dis-
tributed across cell compartments and the CTF is concen-
trated in the nucleus but is also present in the cytoplasm
[34]. A recent report showed that the level of asparaginyl
endopeptidase, which cleaves SET at Asn-175, is increased
in the brains of AD patients [33]. Moreover, asparaginyl
endopeptidase translocates from neuronal lysosomes to
the cytoplasm where SET can be cleaved, an event that
was observed under acidic conditions in vitro and ex vivo
Figure 4 Phosphorylation of tau in adult mouse brain slices treated with recombinant SET protein or Jcasp peptide for 5 h 30 min and
its relationship with methylated PP2A. A) Proteins were extracted from mouse adult brain slices treated with recombinant SET protein or
Jcasp peptide and were analyzed by western blotting (40 μg per lane). Representative western blots of tau hyperphosphorylation at Ser-202,
Ser-404 and Ser-422 and total tau protein are shown. Brain slices not treated with any protein (Ctrl) and brain slices treated with mutated Jcasp
(JA) were used as negative controls. Okadaic acid (OA) was used as positive control. PP2A was also analyzed. Actin was used as internal loading
control. Jcasp or SET internalization induces hyperphosphorylation of the same tau isoforms. B) Quantification of hyperphosphorylation of Ser-202
(n = 8 independent experiments) and Ser-422 (n = 7 independent experiments) in brain slices treated with SET relative to the phosphorylation of
tau at these residues in control cells (set to 100%). Results were normalized to total tau. C-D) Correlation between tau hyper-phosphorylation at
Ser-202 (C) (n = 8 independent experiments) and Ser-422 (n = 7 independent experiments) (D) and methylated PP2A. Phosphorylation at Ser-202
is significantly negatively correlated with methylated PP2A in cells containing recombinant SET.
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models used in this report may explain why SET was not
cleaved. We cannot exclude that SET is somewhat cleaved
in in vivo conditions. Nonetheless, we show that cytoplas-
mic, full-length SET is sufficient to decrease PP2A activity
and induce tau hyperphosphorylation, regardless of the
route of entry of SET to the cytoplasm.
Caspases cleave APP at Asp-664 (APPcc). An increase
of APPcc has already been shown in the brains of AD
patients [37-39]. APPcc may be cleaved further intoamyloid peptide resulting in the release of fragments
containing the Jcasp sequence. APP intracellular domain
generated after amyloid formation, can also be cleaved
by caspases, leading to the formation of analogs of the
Jcasp sequence. We found that the delivery of the Jcasp
peptide to the cytoplasm was sufficient to induce the
translocation of SET and the hyper-phosphorylation of
tau, similar to what we observed with the over-expression
of APPcc [26]. Recently, Asp-664 cleavage of APP in N2A
cells and primary hippocampal neurons was shown to
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activity [48].
The activity of PP2A is low in the brains of AD patients
[12-14]. Specific inhibitors of PP2A such as I1PP2A and
SET, if localized in the cytoplasm, may underlie this im-
paired activity. The low activity of PP2A in the brains of
AD patients may be also partly related to the low level
of PP2A methylated at Leu-309 of the PP2Ac [15,17].
The methylation of this residue is also impaired in the
cortex of transgenic APPxPS1 mice, in the brains of
mice with mutated estrogen receptors, and after the
treatment of N2A cells carrying the human APP Swedish
mutation with OA [17]. We report here that full-length
SET in the cytoplasm interacts with PP2A and decreases
its methylation, thus impairing PP2A activity that leads to
tau hyper-phosphorylation. Our co-immunoprecipitation
experiments confirm the interaction of PP2A with full-
length SET that was reported previously [34]. This inter-
action may impair the methylation of PP2A by inducing a
conformational change that either prevents the interaction
of PP2A with the leucine carboxyl methyltransferase 1 or
stimulates its interaction with the PP2A specific methyles-
terase PME-1 [49-51]. Alternatively, the interaction of
PP2A with SET may lead to a change of localization of
PP2A, which may be preferentially redistributed to non-
raft membrane domains where PP2A methylesterase
PME-1 is exclusively present [51].
The physiological cellular state of phosphorylation
results from an equilibrium between phosphatases and
kinases. Dephosphorylation at Ser-202 and Ser-422 is
dependent on PP2A [3]. Interestingly, we established a
negative correlation between the level of methylated
PP2A and that of tau phosphorylated at Ser-202, con-
firming that the phosphorylation of the Ser-202 site is
directly dependent on PP2A activity [52,44]. This also
suggests that SET, via the methylation of Leu-309 in
PP2Ac, plays an important role in phosphorylation at
Ser-202, which is consistently detected in the brains of
AD patients. In contrast, we did not observe a negative
correlation between the level of methylated PP2A and
tau hyperphosphorylation at Ser-422, despite the fact
that dephosphorylation at this site depends on PP2A.
This suggests that the demethylation of PP2A that is
induced by SET does not substantially affect tau phos-
phorylation at Ser-422. In addition to methylation, PP2A
activity can be modulated by other post-translational modi-
fications. We cannot exclude that the interaction of SET
with PP2A additionally results in the phosphorylation of
PP2A which may be negatively correlated with the
phosphorylation of Ser-422. PP2A is phosphorylated at
Tyr-307 in PP2Ac by a scr kinase, and this phosphory-
lated form is also detected in the brains of AD patients
[11]. Phosphorylation at this residue or at Ser-41 in the
56α subunit, which is mediated by a PKCα, impairsPP2A activity [53]. In our models, we do not know
whether SET induces such post-translational modifica-
tions contributing to the impairment of PP2A activity.
PP2A dephosphorylates tau, which leads to the
stimulation of several tau kinases [53,54]. In our study,
cytoplasmic SET inhibited PP2A; thus, the subsequent
tau hyperphosphorylation observed was the result of
the absence of tau dephosphorylation. Our data show
that Ser-202 becomes highly phosphorylated when
cytoplasmic SET inhibits PP2A activity, in contrast with
the low phosphorylation at Ser-422 in most studies. How-
ever, phosphorylation at Ser-422 is almost undetectable in
humans at the adult stage, emphasizing the relevance of a
low detectable phosphorylation, as observed in the brains
of AD patients [46]. Ser-202 is principally dependent on
GSK3-β [44] whereas Ser-422 is a good substrate for MAP
kinase but not for GSK3-β [46], suggesting that different
sites of tau phosphorylation are regulated by specific ki-
nases. Consequently, cytoplasmic SET, via its inhibition
of PP2A would be differently involved in the regulation
of specific sites of phosphorylation.
In mouse brain slices, we used OA, which is an exoge-
nous natural inhibitor of phosphatases that inhibits 70% of
PP2A activity, as a positive control of tau phosphorylation.
In some cases, the pattern of the tau isoforms that were
hyperphosphorylated by endogenous cytoplasmic SET
or cytoplasmic recombinant SET protein differed from
that observed with OA (Figure 4A and Additional file 1:
Figure S1), which highlights the physiological relevance
of our models. Moreover, both recombinant SET pro-
tein and the Jcasp peptide stimulated the hyperphos-
phorylation of the same tau isoforms (Figure 4A and
Additional file 1: Figure S1), which shows that this Jcasp
peptide that mimics the unmasked domain of APP after
caspase cleavage may be a relevant model for physiopatho-
logical investigations of APPcc. In our ex vivo model, re-
combinant SET protein was successfully internalized in
the cytoplasm of adult mouse brain slices, where it im-
paired PP2A methylation and consequently PP2A activity,
leading to an accumulation of hyperphosphorylated tau.
This model may be used to test molecules that may dis-
rupt the interaction of SET with PP2A and thus prevent
the inhibition of PP2A activity [55].
Overall, these data suggest that when SET is in the
cytoplasm, it reproduces tau hyperphosphorylation ob-
served in the brains of AD patients by impairing the
methylation of PP2A. These findings highly implicate
cytoplasmic SET in the progression of the disease.
Conclusion
We used two ex vivo models to show that full-length,
cytoplasmic SET, independent of its cleavage, inhibits
PP2A activity by decreasing its methylated form, which
leads to tau hyperphosphorylation. These findings link
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of PP2A activity) to the translocation of SET to the neuro-
nal cytoplasm, which are two events that are observed in
the brains of AD patients. In addition, the negative correla-
tion between the level of methylated PP2A and some, but
not all, sites of phosphorylation in tau suggests that tau
phosphorylation is regulated by several mechanisms.
These data provide an important contribution to the
elucidation of the mechanisms involved in AD.
Methods
Antibodies
The various antibodies were purchased and diluted as
follows.
Anti-Disabled-1, AB5840 (Millipore, Saint Quentin en
Yvelines, France) polyclonal rabbit antibody, diluted to
1/1000 for western blotting; anti-I2PP2A/SET (H-120),
sc-25564 (Santa Cruz Biotechnology, Heidelberg, Germany)
affinity purified rabbit polyclonal IgG for endogenous
SET analysis, diluted to 1/2000 for western blotting, to
1/100 for immunocytochemistry, and to 1/100 for SET
immunoprecipitation; anti-Histone clone H11-4, MAB
3422 (Millipore) purified mouse monoclonal IgG1, di-
luted to 1/100 for western blotting; anti-HA mouse
monoclonal antibody MMS 101R (Covance, Eurogentecs,
Angers, France), for recombinant SET protein analysis,
diluted to 1/1000 for western blotting and to 1/200 for
immunocytochemistry; anti-APP-Nter anti-Alzheimer
Precursor Protein A4 clone 22C11 MAB 348 (Millipore)
mouse monoclonal antibody, diluted to 1/1000 for western
blotting; anti-Actin, clone C4 MAB 1501R (Millipore)
mouse monoclonal antibody, diluted to 1/10000 for western
blotting; anti-PP2A C subunit clone 1D6 05–421 (Millipore)
mouse monoclonal antibody, diluted to 1/2000 for total
protein phosphatase 2A western blotting analysis; anti-
methyl-PP2A C subunit clone 2A10 04–1479 (Millipore)
mouse monoclonal antibody, diluted to 1/1000 for western
blotting; anti-p-Tau (Ser 404) sc-12952 (Santa Cruz
Biotechnology) rabbit polyclonal affinity purified anti-
body, diluted to 1/500 for western blotting; anti-p-Tau
(Ser 235) sc-101812 (Santa Cruz Biotechnology) rabbit
polyclonal antibody, diluted to 1/500 for western blot-
ting; anti-Tau (pSer356) 54975 (AnaSpec, San José, CA,
USA) rabbit polyclonal antibody, diluted to 1/100 for
western blotting; anti-Tau (phospho S422) ab4862 (Abcam,
Cambridge, UK), rabbit polyclonal antibody diluted to
1/1000 for western blotting; anti-p-Tau (Ser202), anti-
Human PHF-TAU clone AT8 BR-03 (Innogenetics,
Courtaboeuf, France) mouse monoclonal antibody, di-
luted to 1/1000 for western blotting; anti-Tau mouse
(TAU-5) mAb 577801 (Calbiochem, Merck Chemicals
Limited, Nottingam, UK) mouse monoclonal antibody,
diluted to 1/1000 for total tau analysis in western
blotting.The secondary HRP-antibodies used for the detection of
chemiluminescence were Goat anti-mouse IgG (H+ L)-
HRP conjugate 170–16516 (Bio-Rad, Marnes-La-Coquette,
France), diluted to 1/5000 and ECL anti-rabbit IgG-HRP
NA9340V (GE Healthcare, Dutscher, Brumath, France)
diluted to 1/2000.
Secondary antibodies used for immunocytochemistry
were Donkey anti-rabbit cy3 diluted to 1/500 and Donkey
anti-mouse cy3 diluted to 1/200 (both from Jackson
Immuno-research, Interchim, Montluçon, France).
Jcasp, JA peptides and recombinant SET protein
Peptides of APP 649–664 (Jcasp) and Y653A Jcasp (JA)
both containing penetratin at their N-termini were chemi-
cally synthesized (95-98% purity, Neomps, Strasbourg,
France).
Recombinant SET protein was synthesized as previously
described [27].
Ethics statement
All animal procedures were carried out according to
French and European Union regulations. The protocols
of animal anesthesia were performed according to the
recommendations of the European Economic Community
(86/609/EEC) and the French National Committee (87/
848) of the French government and were approved by the
local ethics committee (Direction départementale des ser-
vices vétérinaires de Paris, service de la protection et santé
animales et de la protection de l’environnement).
Primary cortical neurons
Primary cortical neurons were obtained from E16 Swiss
mouse embryos, as described previously [56]. Dissociated
cells were plated on polyornithine-coated plastic dishes
for biochemical analysis and on glass coverslips for im-
munocytochemistry at a density of 15 × 104 cells/cm2.
The Jcasp peptide or its mutant JA peptide (2 μM final
concentration) or the recombinant SET protein (4 μM
final concentration) were added to the culture medium at
5 days in vitro (DIV) and were incubated for 3 h or 5 h
30 min.
Ex vivo adult mouse brain slices
Male Swiss mice were killed by decapitation and the
brains were put on ice. The cerebellum, olfactory bulb,
and thalamus were discarded. Cross sections of brain
hemispheres were then rapidly cut at 4°C with a McILwain
tissue chopper. Slices (300 μm thick) were suspended in
10 ml of modified Krebs-Ringer phosphate medium (KPR)
(NaCl 123 mM, KCl 2 mM, CaCl2 2.6 mM, MgSO4
0.67 mM, KH2PO4 1.2 mM, Glucose 5.9 mM and
NaHCO3 27 mM) that was equilibrated to pH 7.4 with a
mixture of O2/CO2 (95/5) at room temperature for
30 min, as previously described [57]. The slices were
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nally resuspended in 3 ml of fresh KPR and were incu-
bated in a water bath at 37°C for 15 min under a
constant flow of O2/CO2 (95/5). The slices were then
homogeneously distributed into 4 well culture dishes
(about 16 wells for one mouse brain per experiment)
that were put in a large box placed in a water bath at
37°C under a constant flow of O2/CO2. OA, Jcasp and
JA peptides, and recombinant SET protein were added
to wells at final concentration of 1 μM, 2 μM, 2 μM,
and 4 μM, respectively and were incubated at 37°C for
2 h (OA) or 5 h 30 min (Jcasp, JA and SET). At the end
of incubation the brain slices were distributed in eppen-
dorf tubes, and were rinsed by decantation three times
with the KPR medium to eliminate all traces of OA,
Jcasp, JA and SET. Slices were then homogenized with a
tissue grinder (Kontes glass CO) in different lysis buffers
according to the type of analysis. Protein concentration
was determined with the Micro BCA Protein Assay Kit
(Fischer Scientific, Illkirsch, France).
Slices dedicated to the analysis of tau phosphorylation
by western blotting were extracted in Dulbecco’s PBS
containing DNaseI (30 μg/ml), 1% Triton X-100, prote-
ase inhibitors (Complete, Roche Diagnostics, Mannheim,
Germany) and phosphatase inhibitors (2 mM Na3VO4
and 100 mM NaF).
For the analysis of phosphatase 2A (PP2A) activity after
PP2A immunoprecipitation, the same extraction buffer
without phosphatase inhibitors was used.
For the analysis of total phosphatase activity, slices
were rinsed twice in 50 mM Tris buffer, 0.1 mM CaCl2
pH 7.5 containing protease inhibitors and were extracted
in the same buffer.
For SET and PP2A co-immunoprecipitation experiments,
slices were washed three times in KPR containing protease
and phosphatase inhibitors.
Nuclear and cytoplasmic fractionation
Mouse cortical primary neurons (5 DIV) were incubated
with Jcasp peptide (2 μM) and mouse brain slices were
incubated with either Jcasp peptide (2 μM) or recombi-
nant human SET protein (4 μM) for 5 h 30 min. Primary
neurons and mouse brain slices that were not incubated
with any peptide or recombinant protein under the same
conditions were used as controls. Cells and tissue slices
were rinsed once in cold phosphate buffer saline PBS be-
fore being subjected to sub-cellular fractionation. Nu-
clear and cytoplasmic fractionation was carried out with
the Nuclei EZ Prep Nuclei Isolation Kit (Sigma-Aldrich,
Saint-Louis, MO, USA) following manufacturer’s instruc-
tions. Briefly, scrapped neurons and brain slices were lysed
in cold Nuclei EZ lysis buffer containing protease inhibi-
tors. The homogenised extracts were incubated on ice for
5 min and were then centrifuged for 15 min at 500 × g at4°C. The supernatants were immediately transferred to
clean tubes and centrifuged twice for 15 min at 5000 × g.
The final clarified supernatant corresponding to the
cytoplasmic fractions were stored at −80°C until use for
western blotting. In parallel, the pelleted nuclei were
washed in 4 ml of ice cold Nuclei EZ lysis buffer and
then were resuspended carefully and incubated for
5 min on ice. Washed nuclei were then collected by
centrifugation for 15 min at 500 × g at 4°C. Each pellet
was resuspended in 100 μl of Nuclei EZ storage buffer
and stored at −80°C until use for western blotting.Western blotting
Standard SDS-PAGE western blotting was performed
with 10% Tris–HCl acrylamide home-made gels or pre-
cast 10% gels (Bio-Rad). After electrophoresis, proteins
were transferred onto PVDF membranes (Millipore).
Briefly, membranes were then blocked in 5% low fat milk
in Tris buffer saline, 0.02% Tween 20 (TBST) pH 7.4 and
were incubated overnight at 4°C with primary antibodies
diluted in TBST. After 5 washings in TBST they were in-
cubated with secondary peroxidase-conjugated antibodies
for 1 h at room temperature. After 5 washings, the peroxi-
dase signal was visualized by enhanced chemilumines-
cence, and if necessary, were enhanced by Super Signal
West Femto Maximum Substrate (Fischer Scientific). The
ECL films were scanned with a GS-800 Calibrated Densi-
tometer. Image J software was used for the densitometric
quantification of protein bands.
For western blotting of nuclear and cytoplasmic frac-
tions, histone was used as nuclear marker and Disabled-1
(Dab1) or APP was used as cytoplasmic marker.Immunocytochemistry for SET subcellular localisation
Cells were fixed with 4% paraformaldehyde for 30 min at
room temperature, were rinsed 3 times in (PBS) and
were saturated for 1 h at 37°C with 10% fetal calf serum
in PBS, containing 0.2% Triton X-100. The cells were in-
cubated with antibodies (anti-SET or anti-HA, diluted to
1/200) for 1 h at 37% in saturation buffer, were then
rinsed 3 times in PBS, and were incubated with anti-
rabbit cy3 or anti-mouse cy3 for 1 h at 37°C. After 3
rinses in PBS the coverslips were mounted in a medium
containing DAPI for epifluorescence microscopy. For
confocal microscopy, nuclei were labeled by 0.1 μM TO-
PRO-3 (Life Technologies, Illkirsch, France) for 15 min
at room temperature, the coverslips were then rinsed 3
times in PBS and were mounted with Fluoromount-G
(Clinisciences, Nanterre, France).
Immunofluorescence was analyzed by epifluorescence
microscopy with an Axioplan 2 Zeiss with a x63 plan
Apochromat oil immersion objective (numerical aper-
ture 1.4). Digital images were acquired with a Sony DXC
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same exposure time for each experiment.
The cells were also examined with a TCS SP5 confocal
imaging system equipped with DPSS 561 nm and HeNe
633 nm lasers (Leica Microsystems, Mannheim, Germany).
Eight bit digital images were collected in sequential mode
with a x63 plan Apochromat oil immersion objective, a
numerical aperture of 1.4, a zoom of 3 and the pinhole
size “airy 1”.
Microscopy was performed at the PICPEN platform
(INSERM, UMR 894).
Total phosphatase activity assay
The mouse brain slice lysates were centrifuged at
16000 × g for 15 min at 4°C, then NiCl2 (2.5 mM final)
and p-nitrophenyl phosphate (Sigma-Aldrich) (1 mg/ml
final) were added to supernatants, followed by incubation
for 30 min at 37°C. The reaction was stopped by the
addition of 13% K2HPO4 and the absorbance of released
p-nitrophenol was read at 405 nm.
PP2A immunoprecipitation and PP2A activity assay
The mouse brain slice lysates were centrifuged at
16000 × g for 15 min at 4°C, and the supernatants were
incubated with the PP2A antibody for 2 h (5 μg for
500 μg of protein) at room temperature, followed by
incubation with protein G Sepharose (Fisher Scientific)
for 1 h at room temperature. The immunoprecipitates
were washed carefully twice with 50 mM Tris pH 7.5,
50 mM NaCl followed by two washes in 50 mM pH 7.5
Tris, 0.1 mM CaCl2 pH 7.5. The immunoprecipitates were
then suspended in 50 mM Tris, pH 7.5 assay buffer
containing 0.1 mM CaCl2, 2.5 mM NiCl2 and 1 mg/ml
p-nitrophenyl phosphate as a substrate, and were incu-
bated at 37°C for 30 min. The reaction was stopped by the
addition of 13% K2HPO4 and the absorbance of released
p-nitrophenol was read at 405 nm.
SET-PP2A co-immunoprecipitation
Mouse brain slices incubated for 5 h 30 min with or
without recombinant SET protein were prepared as des-
cribed above. Washed slices were homogenized with a
tissue grinder (Kontes glass CO) in immunoprecipitation
buffer (Hepes 10 mM, NaCl 150 mM, CaCl2 2 mM, Triton
X-100 1% pH 7.4) containing protease and phosphatase
inhibitors and the resulting lysates were centrifuged at
16000 × g for 45 min at 4°C. Proteins were quantified
with the Micro BCA Protein Assay Kit (Fischer scientific).
Lysates containing 1 mg of protein in 400 μl were pre-
cleared by incubation with 30 μl of protein A Sepharose
CL-4B (Fischer Scientific) for 1 h at 4°C on a rotating
wheel. The clear supernatant was incubated overnight at
4°C on a rotating wheel with or without the polyclonal
anti-SET. A total of 30 μl of protein A Sepharose CL-4Bwas then added to each tube for 2 h at 4°C on a rotating
wheel. The samples were centrifuged at 1000 × g for
10 min at 4°C, and were then washed twice with immu-
noprecipitation buffer and a third time in the same buf-
fer without Triton X-100. Samples were then suspended
in NuPage LDS Sample Buffer (Bio-Rad) adjusted to 5%
β-mercaptoethanol and 5% SDS, were boiled for 5 min
and were centrifuged for 5 min at 16000 × g at room
temperature. The supernatants were then analyzed by
western blotting.
In some experiments, the Pierce Crosslinking Kit (Fischer
Scientific) was used according to the manufacturer’s
procedure. Briefly, the pre-clearing step was performed
with a control agarose resin for 1 h at 4°C on a rotating
wheel. The polyclonal SET antibody was covalently
coupled to protein A/G Plus agarose and was incubated
with the pre-cleared lysate over night at 4°C on a rotat-
ing wheel. After four washes - the last without Triton
X-100 - the immunoprecipitated proteins were eluted
with 30 μl of the kit elution buffer in a tube containing
5 μl of 1 M Tris pH 9.5 to neutralize the low pH of the
elution buffer.
Real time PCR for mRNA quantification
Neurons at 5 DIV were incubated for 1 h 30 min, 2 h
30 min, 3 h 30 min or 5 h 30 min with 2 μM of Jcasp pep-
tide or 2 μM of Penetratin. The medium was removed and
the cells were washed once in PBS and then collected by
scraping. Total RNA was extracted with the RNeasy mini
kit and was treated with DNaseI (Qiagen, Courtaboeuf,
France). cDNA was prepared from total RNA samples
with the High Capacity cDNA Reverse Transcription kit
(Life Technologies, Saint Aubin, France). Briefly, 20 μl of
reaction mixture containing 100 ng of total RNA, 1X re-
verse transcription buffer, 1 mM of each dNTP, 1X reverse
transcription random primer and 50U of MultiScribe re-
verse transcriptase were incubated at 25°C for 10 min
followed by incubation at 37°C for 2 h. The reaction was
stopped by heating at 85°C for 5 sec. Real time PCR was
performed with an Abi Prism 7000 and the Absolute
SYBR Green ROX Mix (Fischer Scientific). A total of
25 ng of cDNA was mixed with 0.07 mM of each primer,
1X SYBR Green Mix and PCR-grade water to a final
volume of 25 μl. The cycling conditions for all primers
(Set forward: TTACTGACCATTCTGACGCA, Set re-
verse: CTGCCTCTCCTTCTTCATCA, Gapdh forward:
CCAACACTGAGCATCTCCCT and Gapdh reverse:
GGGTGCAGCGAACTTTATTG) were 50°C for 2 min,
then 95°C for 15 min followed by 40 cycles consisting of
two steps, 15 sec at 95°C and 1 min at 60°C. The PCR
program was completed by a melting temperature ana-
lysis consisting of 15 sec at 95°C, 20 sec at 60°C and
then steps through which temperature ranged from 60
to 95°C. Amplification plots were produced to calculate
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sus log cDNA dilution were generated for both target
(SET) and reference (GAPDH) genes. All reactions were
done in triplicate and the average Ct was used. Relative
quantification was calculated with the 2-ΔΔCt method.
Gene expression in Jcasp peptide treated neurons was
calculated relative to that of Penetratin treated cells.
Statistical analysis
Significance was assessed with the analysis of variance
(ANOVA) and post-hoc Scheffe’s test (StatView). Results
were expressed as mean value ± SEM.
Additional file
Additional file 1: Figure S1 Differences in hyperphosphorylated tau
isoforms in cells treated with OA, Jcasp peptide or recombinant SET
protein. Mouse brain slices were treated with recombinant SET protein
or Jcasp peptide for 5 h 30 min, and proteins were then extracted and
prepared (40 μg per lane) for western blotting. Various residues that may
be hyperphosphorylated on tau were analyzed. Okadaic acid (OA) was
used as positive control. Brain slices not treated with recombinant SET
were used as a control (Ctrl). Jcasp and SET induce hyperphosphorylation
of the same tau isoforms. In some cases these hyperphosphorylated tau
isoforms differ from those induced by okadaic acid (OA). Representative
examples of two independent experiments are shown (A, B). Note that
for the same mouse brain, the tau isoforms phosphorylated at the
Ser-422 epitope were identical for OA and recombinant SET, contrary to
what we observed for Ser-202 (B).
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